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Article

Cancer immunoediting
by the innate immune system
in the absence of adaptive immunity
Timothy O’Sullivan,1 Robert Saddawi-Konefka,1 William Vermi,2
Catherine M. Koebel,3 Cora Arthur,3 J. Michael White,3 Ravi Uppaluri,4
Daniel M. Andrews,5,6 Shin Foong Ngiow,5,6 Michele W.L. Teng,5,6
Mark J. Smyth,5,6 Robert D. Schreiber,3 and Jack D. Bui1
1Department

of Pathology, University of California at San Diego, La Jolla, CA 92093
of Pathology, University of Brescia, 25121 Brescia, Italy
3Center for Immunology, Department of Pathology and Immunology and 4Department of Otolaryngology,
Washington University School of Medicine, St. Louis, MO 63110
5Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
6Department of Pathology and Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Melbourne,
Victoria 3010, Australia

Cancer immunoediting is the process whereby immune cells protect against cancer formation by sculpting the immunogenicity of developing tumors. Although the full process
depends on innate and adaptive immunity, it remains unclear whether innate immunity
alone is capable of immunoediting. To determine whether the innate immune system can
edit tumor cells in the absence of adaptive immunity, we compared the incidence and
immunogenicity of 3methylcholanthrene-induced sarcomas in syngeneic wild-type,
RAG2/, and RAG2/x Gc/ mice. We found that innate immune cells could manifest
cancer immunoediting activity in the absence of adaptive immunity. This activity required
natural killer (NK) cells and interferon G (IFN-G), which mediated the induction of M1
macrophages. M1 macrophages could be elicited by administration of CD40 agonists,
thereby restoring editing activity in RAG2/x Gc/ mice. Our results suggest that in the
absence of adaptive immunity, NK cell production of IFN-G induces M1 macrophages,
which act as important effectors during cancer immunoediting.

CORRESPONDENCE
Jack D. Bui:
jbui@ucsd.edu
Abbreviations used: eCAD,
epithelial cadherin; Gas3,
growth arrest–specific gene 3;
iNOS, inducible nitric oxide
synthase; IHC, immunohistochemistry; MCA, 3methylcholanthrene; NKG2D, natural
killer group 2D; PDA, pancreatic
ductal adenocarcinoma; qPCR,
quantitative PCR; TAM,
tumor-associated macrophage.

Immune cells can infiltrate a developing tumor
mass and either promote or inhibit tumorigenesis (Balkwill and Coussens, 2004; Ben-Neriah
and Karin, 2011; Schreiber et al., 2011). Cancer
immunoediting describes the process whereby
the interaction between immune cells and tumor
cells either eliminates the developing tumor,
holds it in a state of growth dormancy, or generates a tumor cell repertoire that is capable of
survival in immune-competent hosts (Shankaran
et al., 2001; Dunn et al., 2004b; Vesely et al.,
2011). Several studies have revealed the contribution of adaptive and innate immunity in
cancer immunoediting (Shankaran et al., 2001;
Dunn et al., 2004a; Smyth et al., 2006; Dunn
et al., 2005; Smyth et al., 2005; Street et al., 2004;
Crowe et al., 2002; Takeda et al., 2002; Smyth
T. O’Sullivan and R. Saddawi-Konefka contributed equally
to this paper.
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et al. 2001), but it is not clear whether the unmanipulated innate immune system can suppress
tumor formation without adaptive immunity.
In this study, we examined the ability of
the innate immune system to control tumor
formation in the absence of adaptive immunity. It has been shown that natural killer cells
(NK; Smyth et al., 2002; Raulet and Guerra,
2009) and classically activated M1 macrophages
(Sica et al., 2008; Lewis and Pollard, 2006)
support a Th1 response that can ultimately lead
to tumor rejection in the presence of adaptive
immunity, but it is not clear whether these cells
interact in the absence of adaptive immunity
to suppress tumor formation in primary tumor
© 2012 O’Sullivan et al. This article is distributed under the terms of an
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six
months after the publication date (see http://www.rupress.org/terms). After six
months it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/
licenses/by-nc-sa/3.0/).
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into RAG2/ recipients, RAG2/x Gc/ regressor sarcoma
cell lines formed tumors that became heavily infiltrated with
M1 macrophages. The infiltration of M1 macrophages was
associated with tumor editing and required host Gc and IFN-G
activity. In contrast, in the absence of Gc and IFN-G function,
RAG2/x Gc/ regressors were infiltrated with more M2
macrophages, which can promote tumor formation (Sica et al.,
2008).We also found that M1 macrophages can be elicited by
CD40 agonistic antibodies to restore the editing capacity of
RAG2/x Gc/ mice. These studies document that components of the innate immune system present in RAG2/ mice
can manifest certain types of cancer immunoediting capacity
in the absence of adaptive immunity and point, specifically, to
M1 macrophages as important effectors in this process.
RESULTS
MCA-induced sarcoma incidence is increased in RAG2/x
Gc/ mice compared with syngeneic RAG2/ and WT mice
To determine whether the innate immune system of RAG2/
mice was capable of tumor immunosurveillance, we compared
the incidence of MCA-induced sarcomas in immunologically
intact WT C57BL/6 mice to that of C57BL/6 mice with defects in either adaptive immunity only (RAG2/ mice) or in
both adaptive and innate immunity (RAG2/x Gc/ mice).
Fig. 1 shows that the incidence of sarcomas was higher in
RAG2/x Gc/ mice compared with RAG2/ mice at all
doses tested. For example, at a dose of 25 μg MCA, the incidence of sarcomas in WT, RAG2/, and RAG2/x Gc/
mice was 35, 60, and 80%, respectively. In addition, at MCA doses
of 25 or 100 μg, RAG2/x Gc/ mice developed sarcomas
slightly faster than RAG2/ mice, indicating that the innate
immune system in RAG2/ mice controlled MCA-induced
tumor outgrowth to some extent. The difference in tumor incidence between cohorts of mice were not caused by inherent
strain differences, as heterozygote RAG+/ littermates did not
show differences compared with WT mice (unpublished data).
Growth of MCA-induced sarcoma cell lines
derived from RAG2/x Gc/ mice is inhibited
when transplanted into syngeneic WT mice
To study tumor editing, low-passage cell lines were
derived from primary MCA tumor masses generated in C57BL/6 WT, RAG2/, and RAG2/x
Gc/ mice, and the immunogenicity of each cell
line was assessed by transplanting them into naive
WT syngeneic mice and monitoring their growth
Figure 1. RAG2/x Gc/ mice are more susceptible
to MCA-induced sarcomas than syngeneic RAG2/
and WT mice. The indicated dose of MCA was injected
into the subcutaneous space of mice, and sarcoma formation was monitored over time. All cohorts consisted of
20 mice. Tumor-positive mice were defined as those that
harbored a progressively growing mass ≥25 mm2. Similar
results were found in a repeat experiment that included
the 5 and 25 μg doses.
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models. In contrast, other studies have found that the innate
immune system can promote tumor formation via alternatively activated M2 macrophages (Gordon and Taylor, 2005)
that augment angiogenesis and promote tissue invasion. M2
macrophages also inhibit the formation of antitumor adaptive immunity, and therefore it is possible that innate immunity would promote tumor formation in the absence of
adaptive immunity.
Using the 3methylcholanthrene (MCA) model of sarcomagenesis, we previously found that the immune system
in WT mice could edit tumors more effectively than the
immune system in RAG2/ mice (which lack adaptive
immunity; Shankaran et al., 2001; Takahashi and Yamanaka,
2006), but we did not assess whether tumors from RAG2/
mice were edited by the innate immune system. Because
RAG2/ mice and other immunodeficient mice such as
nude and SCID mice are routinely used as “immunodeficient”
models for xenotransplantation and preclinical studies, it is critical to assess whether the innate immune system in these mice
could have an impact, positive or negative, on tumor growth.
Toward this end, we set out to quantitate tumor editing in
WT versus RAG2/ versus RAG2/x Gc/ mice.
RAG2/x Gc/ mice lack all lymphocytes, including
NK, NK-T, GD-T, classical CD4+,and CD8+ AB-T cells and
B cells, and thus show deficits in both innate and adaptive
immunity. If cells of the innate immune system could hinder
tumor growth, then we would expect RAG2/x Gc/ mice
to demonstrate increased tumor incidence and decreased
tumor editing compared with RAG2/ mice. Indeed, when
we compared MCA-induced sarcoma incidence and tumor
cell immunogenicity between the groups of mice, we found
both increased incidence and immunogenicity of MCAinduced sarcomas in RAG2/x Gc/ mice compared
with RAG2/ mice, which, consistent with previous results
(Shankaran et al., 2001), had increased incidence and immunogenicity of tumors compared with WT mice.When transplanted
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sarcoma cell lines from 15 RAG2/ and 9 WT mice formed
tumors in 64 and 97% of WT recipients, respectively. These
results were reproduced in an independent MCA induction
experiment, and the combined results of these two experiments, encompassing 71 total MCA-induced sarcoma cell lines
transplanted into 474 WT mice, 94 RAG2/ mice, or 51
RAG2/x Gc/ mice, are shown in Table 1. Altogether,
these results support the hypothesis that tumors from mice
with greater immunodeficiency undergo decreased levels
of immunoediting.
Tumor cell lines generated in RAG2/x Gc/ mice
show an increased regressor frequency compared
with cell lines from WT and RAG2/ mice
We reported previously that the percentage of regressors within
a group of MCA-induced sarcoma cell lines, the “regressor
frequency” (Fig. 2) was 40% when the MCA-induced sarcoma
cell lines were generated in RAG2/ mice and 0% when the
cell lines were generated in WT mice (Shankaran et al., 2001).
These percentages are remarkably reproducible, and have
remained so even when experiments have been conducted in
our three independent laboratories in La Jolla, CA, St. Louis,
MO, and Melbourne, Australia (Fig. 4). Specifically, we found
a consistent regressor frequency of 0% when MCA-induced
sarcoma cell lines are generated in WT mice (50 cell lines
from two strains and four independent experiments). Notably,
MCA-induced sarcoma cell lines derived from RAG2/ mice
displayed a 30–44% regressor frequency (82 cell lines from
3 strains and 4 independent experiments). MCA-induced sarcoma cell lines derived from RAG2/x Gc/ mice had the

Figure 2. Generation of MCA sarcoma cell lines of varying immunogenicities to study cancer immunoediting by innate and adaptive immunity.
(A) The carcinogen MCA is administered to syngeneic mice with three levels of immune function. (n ≥ 20 mice for each cohort). (B) The immunogenicity
of the MCA sarcomas is postulated to be heterogeneous. (C) MCA sarcoma cell lines are generated from each tumor mass and transplanted into syngeneic
WT mice (n > 5 for each cell line) to assess growth. (D) Shown is the % growth of each cell line after transplant into WT mice. Cell lines that grow in
<51% of the mice are termed regressors. Cell lines that grow in >50% of mice are termed progressors. (E) For each genotype, the percentage of tumor
cell lines that displayed a regressor growth pattern is plotted. The “percent regressor tumors” is postulated to be inversely correlated with the quantity of
immune pressure that is occurring during tumor formation in each mouse genotype.
JEM Vol. 209, No. 10
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(Fig. 2). As described previously (Kripke, 1974; Boon and
Kellermann, 1977; Flood et al., 1987; Shankaran et al., 2001;
Dunn et al., 2005), we observed two divergent growth phenotypes among the transplanted sarcomas: a regressor phenotype, defined by a failure to form a mass of >9 mm in diameter
in >50% of transplantations into syngeneic WT mice, and a
progressor phenotype, defined by the formation of masses
>9 mm in >50% of transplantations into WT mice. When we
examined groups of MCA-induced sarcoma cell lines generated from WT, RAG2/, and RAG2/x Gc/ mice, we
found that the proportion of regressor MCA-induced sarcoma
cell lines was 0/9 WT, 3/10 RAG2/, and 6/10 RAG2/x
Gc/ (Fig. 3 A, right). All cell lines grew when transplanted
into RAG2/ mice (Fig. 3 A, left), indicating that their
rejection was caused by the adaptive immune system and
was not simply a failure to grow in vivo.
To determine the overall immunogenicity of each group of
tumors, we examined the tumor-free survival of large cohorts of
WT and RAG2/ mice challenged with panels of tumor cell
lines derived from WT, RAG/, or RAG2/x Gc/ mice
(Fig. 3 B). All MCA-induced sarcoma cell lines formed tumors
in RAG2/ mice by 36 d after tumor cell transplant (Fig. 3 B,
top). In contrast, the kinetics and frequency of tumor formation in WT recipients was dependent on the level of immune
function of the original source from which the tumor cells
were derived. Specifically, when 17 tumor cell lines derived
from RAG2/x Gc/ mice were transplanted into a total of
132 naive, syngeneic WT mice, only 46% of the mice formed
tumors by 70 d after transplant (Fig. 3 B, bottom; P < 0.001 for
all comparisons). Over a similar time course, MCA-induced
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highest regressor frequency (60–70%), indicating that as a group, these cell lines were
the most immunogenic and least edited.
RAG2/x Gc/ regressors
undergo editing when transplanted
into RAG2/ mice
Because regressor cell lines generated
from RAG2/x Gc/ mice displayed
the highest levels of immunogenicity and,
subsequently, the lowest levels of immunoediting compared with RAG2/ and
WT mice, we hypothesized that the innate immune system of RAG2/ mice
could edit these tumor cell lines in vivo.
We tested this by transplanting two independent sarcoma cell lines generated
from RAG2/x Gc/ mice into either
RAG2/ or RAG2/x Gc/ mice. To
determine if in vivo passaging altered the
immunogenicity of these cell lines, tumor
masses were harvested at day 25 and converted into cell lines. When these cell lines
were transplanted into WT mice, 88% of
RAG2/-passaged tumor cell lines formed
progressively growing tumor masses by
day 40 compared with 46% of RAG2/x
Gc/–passaged and 10% of unpassaged
cell lines (Fig. 5 A; P = 0.025). These results suggest a higher level of editing by
the innate immune system in RAG2/
versus RAG2/x Gc/ mice but also
indicate that there is some level of measurable tumor sculpting in RAG2/x Gc/
mice, which could be caused by residual
immune function or a nonimmunological editing process.
1872
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Figure 3. A majority of MCA-induced sarcoma cell lines derived from RAG2/x Gc/
mice cannot form tumors when transplanted
into syngeneic WT mice. MCA-induced sarcoma
cell lines were derived from tumors generated in
syngeneic C57BL/6-strain WT, RAG2/, and
RAG2/x Gc/ mice. These cell lines were transplanted into syngeneic RAG2/ (n ≥ 2 for each
cell line) or WT (n ≥ 5 for each cell line) hosts,
and tumor growth was measured over time.
(A) The mean growth for each cell line is shown
(open symbols = regressor cell lines; closed symbols = progressor cell lines). (B) The percentage of
WT mice that developed tumors is shown for
group of cell lines. Tumor-free mice were defined
as having a nonenlarging mass <9 mm in average
diameter. The number of cell lines and mice are
indicated in the figure.
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Table 1. A summary of two independent MCA induction
immunoediting experiments
Tumor group

Growth in WT

Growth in RAG/
xGc/

100% (22/22)

ND

100% (15/15)

ND

100% (27/27)

ND

ND

100% (21/21)

100% (30/30)

ND

ND

100% (30/30)

A total of 71 MCA sarcoma cell lines were generated from the indicated mice and
then transplanted into 474 WT, RAG/, or RAG2/x Gc/ mice, and tumor
growth was monitored. Regressor frequencies from these experiments (1 and 2)
are shown in Fig. 4. ND, not determined.

NK cells do not preferentially kill regressor versus
progressor tumor cells
Having shown that Gc is important for the ability of innate
immunity to control and edit MCA-induced sarcomas, we
predicted that NK cells, dependent on Gc for development
(Cao et al., 1995), would participate in this editing process
in vivo. To explore whether NK cells preferentially recognize

MHC class II–positive macrophages are selectively
present in regressor tumors during immunoediting
We therefore redirected our focus on myeloid cells, as they
represent the major hematopoietic lineage cell type that infiltrates either rejecting or progressively growing tumors (Sica
et al., 2008). To examine this issue, two RAG2/x Gc/ regressor cell lines were transplanted into either RAG2/ or
RAG2/x Gc/ hosts, and tumors were harvested at day 15
and analyzed by immunohistochemistry (IHC) to assess the
number and phenotypes of infiltrating myeloid cells. Strikingly,
we observed significantly higher numbers of MHC class II–
positive cells in tumors growing in RAG2/ versus RAG2/x
Gc/ hosts (Fig. 6, A and B; P = 0.00156 and 0.0071,
respectively). This was likely caused by increased MHC class
II induction rather than an increase in macrophages, as no
differences were detected in the total number of macrophages infiltrating tumors growing in either RAG2/ or
RAG2/x Gc/ hosts, as detected by the tissue macrophage
marker CD68 (Fig. 6 B, right). A similar preferential accumulation of MHC class II–positive cells was also observed in
unedited versus edited tumors growing in RAG2/ mice
(Fig. 6, C–E). In these studies, total monocyte-lineage cells
(as marked flow cytometrically by F4/80)
was similar between edited and unedited
tumors, but the percentage of F4/80+
cells that expressed high levels of MHC
class II was higher in unedited versus
edited tumors.
Figure 4. The frequency of regressor cell
lines is greater from tumors generated in
RAG2/x Gc/ mice compared with WT and
other immune deficient mice. A summary of
two MCA-induction experiments performed in
this manuscript is plotted in the context of previous MCA-induction experiments. Previously
published experiments are included for comparison purposes and are from previous studies
(Shankaran et al., 2001; Dunn et al., 2005; Koebel
et al., 2007). Absolute numbers of regressors/total
number of cell lines tested is shown next to the
bar for each experiment.

JEM Vol. 209, No. 10
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9 WT tumors into 87 97% (84/87)
WT or 22 RAG hosts
(exp 1)
15 RAG tumors into 64% (77/120)
120 WT or 7 into
15 RAG hosts (exp
1)
46% (61/132)
17 RAGxGc tumors
into 132 WT or 10
into 27 RAG hosts
(exp 1)
10 WT tumors into 35 100% (35/35)
WT or 21 RAGxGc
hosts(exp 2)
60% (30/50)
10 RAG tumors into
50 WT or 30 RAG
hosts (exp 2)
30% (15/50)
10 RAGxGc tumors
into 50 WT or 30
RAGxGc hosts
(exp 2)

Growth in
RAG/

regressors over progressors, we performed standard chromium
release cytotoxicity assays (Bui et al., 2006) and also examined
the NK cell content in regressor versus progressor tumors.
We found that the overall susceptibility to NK cell killing of
10 MCA-induced sarcoma cell lines from RAG2/x Gc/
mice did not differ from that of 10 MCA-induced sarcoma
cell lines from RAG2/, or 9 MCA-induced sarcomas from
WT mice (Fig. 5 B). Even when all tumors were grouped
based on phenotypic growth in WT mice—grouped into progressors or regressors—we observed no difference in NK cell–
specific lysis (Fig. 5 B). Additionally, we did not detect a
difference in NK1.1+ cell infiltration (Y5%) into any of the
MCA-induced sarcomas after they were transplanted into
RAG2/ mice (Fig. 5 C).
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infiltration did not differ between hosts as determined by CD68+
events (Fig. 7 D). These results demonstrate that NK cells and
IFN-G may facilitate editing by activating macrophages.
Tumor-associated macrophages (TAMs) from regressor
tumors display an M1 phenotype and require NK cells
and IFN-G for polarization in vivo
Because the MHC class II+ macrophages required IFN-G
for their accumulation, we hypothesized that these macrophages were classically activated (Gordon and Taylor, 2005)
M1 macrophages and performed immunophenotyping to
detect the presence of tumor-associated M1 or M2 macrophages, known to have anti- or pro-tumor functions, respectively (Lewis and Pollard, 2006; Sica et al., 2008). For this
purpose, we used a combination of IHC and FACS analysis
combined with defining cytokine production in freshly harvested tumors. In all cases, we analyzed no fewer than three
tumors across at least two experiments. We first performed
IHC analysis for the M2-type macrophage marker CD206
and compared the staining pattern to that of MHC class II
(known to be up-regulated on M1 macrophages versus M2
macrophages; Fig. 8 A). We found that regressor tumors
harvested from RAG2/ mice had the highest percentage
of class II high events (29%) and lowest percentage of

Figure 5. RAG2/x Gc/ regressors are edited when transplanted into RAG2/ mice, but are not specifically recognized by NK cells. Two
independent MCA-induced sarcoma cell lines generated from RAG2/x Gc/ mice were transplanted into syngeneic RAG2/x Gc/ or RAG2/ mice,
and tumor masses were harvested at day 25 and converted into “passaged” daughter cell lines, which were transplanted into syngeneic WT mice (number of
cell lines and mice are shown in the figure), and (A) the percentage of WT mice that remained tumor-free is shown for each group of cell lines. Tumor-free
mice were defined to have a nonenlarging mass <9 mm in average diameter by day 40. (B) MCA sarcoma cell lines were cultured with IL-2–activated
NK cells in a 5-h chromium release cytotoxicity assay and specific lysis normalized to YAC-1–specific lysis is plotted for each cell line based on immune background and phenotype. (C) Regressor and progressor cell lines were transplanted into RAG-deficient mice and analyzed for infiltrating NK cells by FACS.
1874
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Editing of regressor tumor cells from RAG2/x Gc/ mice
and induction of MHC class II on tumor-infiltrating cells
requires NK cells and IFN-G production in vivo
Because Gc was important for editing, but NK cell–dependent tumor cell killing was not, we hypothesized that NK
cell–derived IFN-G was critical for the editing process we
observed in RAG2/ mice. We therefore transplanted a regressor cell line derived from a RAG2/x Gc/ mouse into
RAG2/ recipients treated either with the neutralizing H22
IFN-G–specific monoclonal antibody (mAb), an NK1.1 specific monoclonal antibody (PK136), or a control mAb (PIP).
Tumors were harvested at day 20 and converted into cell
lines, which were subsequently transplanted into naive, syngeneic WT hosts to measure tumor-free survival. We observed
a statistically significant increase in the survival of WT mice
transplanted with MCA-induced sarcomas that had been passaged through NK cell–depleted and IFN-G–neutralized mice
versus control mice (Fig. 7, A and B; P = 0.0042 and 0.0016,
respectively), indicating that NK cells and IFN-G play critical
roles in activating the editing capacity of the innate immune
system in RAG2/ mice. Analysis of tumor cross sections
by IHC at day 20 showed MHC class II–positive macrophages were significantly reduced with anti–IFN-G treatment
(Fig. 7, C and D; P = 0.0432), even though total macrophage
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CD206+ events (33%). In contrast, tumors harvested from
both RAG2/ mice depleted of IFN-G or RAG2/x Gc/
mice had significantly lower percentages of class II events (12
and 10%, respectively) and significantly higher percentages of
CD206+ events (60 and 70%, respectively; Fig. 8 A). Thus,
IHC analysis suggested that M1-phenotype macrophage accumulation within tumors requires both IFN-G and Gc.We next
used FACS analysis to gate on TAM subsets using combinations of CD11b, Ly6C, and MHC class II to differentiate
between M1 and M2 macrophages (Fig. 8 C) as previously
described (Movahedi et al., 2010). This gating strategy identified M1 macrophages as MHC class IIhi, Ly6Clo, CD206lo,
F4/80hi cells and M2 macrophages as MHC class IIlo, Ly6Clo,
CD206hi, F4/80hi cells (Fig. 8, C and D). This analysis showed
JEM Vol. 209, No. 10

that regressor tumors contained significantly higher percentages
of M1 macrophages when isolated from RAG2/ mice
treated with control mAb PIP (56%) compared with either
RAG2/ mice treated with anti-NK1.1 mAb (28%), neutralizing IFN-G mAb (37%), or RAG2/x Gc/ (20%) mice
(Fig. 8 B, top; P < 0.0001 for all populations). Conversely, M2
macrophage percentages were slightly increased in tumors isolated from RAG2/ mice treated with anti–IFN-G (36%) and
RAG2/x Gc/ mice (37%), but not anti-NK1.1–treated
mice (27%) compared with control RAG2/ mice (28%;
Fig. 8 B, bottom; P = 0.0007 and 0.002, respectively), confirming our IHC results. Tumor cell suspensions isolated from the
different groups of mice did not show differences in total
numbers of CD45+ or CD11b+ cells (unpublished data), thus
1875

Downloaded from jem.rupress.org on December 11, 2012

Figure 6. MHC class II+ macrophages preferentially infiltrate unedited regressors. (A) Representative images of tumor sections from RAG2/
or RAG2/x Gc/ hosts stained for MHC class II. (B) Quantification of MHC class II+ events and CD68+ events in tumor sections is shown. (C–E) Regressor
and progressor cell lines were transplanted into RAG2/ mice and analyzed for activated MHC class II+ macrophages. (C) Representative FACS plots of
three regressor and three progressor tumors are shown. Cells were gated on a CD45+PI population. (D) Percentages of activated monocyte-lineage
(F4/80+) cell populations are shown for regressor and progressor tumor masses. Each symbol represents a different tumor cell line transplanted into
1–3 RAG2/ mice. (E) Frozen tumor sections of progressor and regressor tumor masses growing in RAG2/ mice were stained for MHC class II. Nuclei
were counterstained with hematoxylin. Bar, 100 Mm. **, P < 0.01. Error bars are represented by ± SEM. IHC results were reproduced at least once.
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Figure 7. NK cells and IFN-G are necessary for innate editing of a
regressor tumor and M1 macrophage accumulation. Regressor cell
line 2 was transplanted into RAG2/ mice treated with anti-NK1.1,
IFN-G–blocking antibody, or control antibody, after which tumor growth
was measured and passaged cell lines were generated. (A and B) The
passaged cell lines were then transplanted into syngeneic WT hosts
(number of cell lines and mice are indicated) and tumor-free survival was
measured. Tumor-free mice were defined to have a nonenlarging mass
<9 mm in average diameter by day 40. Tumor sections from RAG2/ hosts
were stained for MHC class II (C) and quantitated (D). *, P < 0.05. Error
bars are represented by ± SEM. Results were reproduced at least once.

ruling out the possibility that the differences observed in TAM
subsets were caused by differential recruitment of immune
cells in mice lacking either IFN-G or Gc function.
1876

Polarization of M1 macrophages in vivo by administration
of a CD40 agonist induces editing in RAG2/x Gc/ mice
CD40 agonist administration in vivo has been shown to have
antitumor properties (Buhtoiarov et al., 2005; Rakhmilevich
et al., 2008) by activating TAMs to become tumoristatic
through production of nitric oxide (Lum et al., 2006). We
hypothesized that CD40 agonist treatment would activate
macrophages in tumors growing in RAG2/x Gc/ mice,
thereby leading to editing of cancer cells in vivo. To test this,
a regressor cell line was transplanted into RAG2/x Gc/
mice receiving a single injection of either control IgG or antiCD40 agonist monoclonal antibodies, tumor masses were
harvested, and cell lines were generated and transplanted into
WT mice.We found that cell lines from CD40 agonist-treated
RAG2/x Gc/ mice formed tumor masses in 100% of WT
recipients, whereas cell lines from isotype-treated RAG2/x
Gc/mice formed tumors in 33% of WT recipients in
RAG2/x Gc/ mice (Fig. 9 A; P = 0.0009). We then analyzed the quantity of M1 macrophages in harvested tumor
cell suspensions and found that M1 macrophage percentages
Tumor editing by macrophages and NK cells | O’Sullivan et al.
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To test a functional marker of TAM polarization, we examined supernatant of matched tumor cell suspensions cultured
in vitro. Cell suspensions from tumors growing in control
RAG2/ mice contained high levels of IL-1A and IFN-G
and produced levels of IL-6 and TNF that were similar to
bone marrow–derived macrophages stimulated with LPS
and IFN-G, indicative of a classically activated M1 macrophage
cytokine profile. In contrast, cell suspensions derived from
tumors derived from anti-IFN-G–treated RAG2/ mice and
RAG2/x Gc/ mice produced significantly lower levels
of each cytokine (Fig. 8 E; P < 0.0001 for all comparisons).
We did not detect IL-10, or IL-4 production in any of the
cultures, indicating that the M2 TAMs are not identical to
alternatively activated M2 macrophages found in certain
infections. No cytokine production was observed in cultures
of the tumor cell line alone (unpublished data). This result
demonstrates that the cytokines that were detected in the cell
suspensions derived from in vivo growing tumors can be
attributed to the immune subsets that infiltrate the tumor.
To identify the phenotype of the infiltrating macrophages,
cell suspensions from regressor tumors transplanted into 10
RAG2/x Gc/ or 10 RAG2/ mice were harvested at
day 15, and M1 and M2 TAMs were sorted and characterized by quantitative PCR, using markers known to be associated with an M1-type phenotype (TNF and inducible nitric
oxide synthase [iNOS]; Martinez et al., 2009) or with an
M2-type phenotype (arginase and epithelial cadherin [eCAD]),
growth arrest–specific gene 3 (Gas3; Ghassabeh et al., 2006;
Fig. 8 F). Macrophages sorted from tumors transplanted into
RAG2/ hosts that were identified as M1-type MHC class
IIhi, Ly6Clo, CD206lo, F4/80hi displayed high levels of both
TNF and iNOS transcript compared with macrophages sorted
from RAG2/x Gc/ that were identified as M2-type MHC
class IIlo, Ly6Clo, CD206hi, F4/80hi and displayed higher transcript levels of arginase, eCAD, and Gas3.
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were doubled in mice treated with CD40 agonist (36%) compared with control treatment (18%; Fig. 9 B, top; P = 0.0003).
Correspondingly, M2 macrophages were decreased (23 vs.
15%) by anti-CD40 agonist treatment (Fig. 9 B, bottom; P =
0.0151). These results suggest that TAMs can be activated in
RAG2/x Gc/ mice to effectively edit tumors in vivo.
DISCUSSION
The cancer immunoediting hypothesis predicts that tumors
arising in immune-deficient individuals will be more immunogenic than tumors that develop in immune-competent individuals. Although this concept is achieving wide acceptance,
the relationship between the degree of host immune deficiency
and the extent of cancer immunoediting have not yet been
examined. In this study, we provide evidence that the extent
JEM Vol. 209, No. 10

of host immune-deficiency directly correlates with the level
of cancer immunoediting. In doing so, we document that the
innate immune system present in RAG2/ mice can mediate to some extent the immunosurveillance and immunoediting of MCA-induced sarcomas. This editing activity is
associated with M1 macrophages, IFN-G, Gc, and NK cells.
Consistent with our previous studies (Shankaran et al.,
2001; Koebel et al., 2007; see Fig. 4 for these data plotted in
the context of our new data), we found that tumors arising in
RAG-deficient mice are unedited and as a group, more immunogenic. Our evidence is based on studies of over 150 cell
lines generated during a decade of experimentation performed
in two separate sites, across two strains of mice, and using both
RAG1- and RAG2-deficient models. A striking finding from
our studies is that the regressor frequency of MCA-induced
1877
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Figure 8. NK cells and IFN-G are required to polarize TAMs toward an M1-type phenotype. Regressor cell line 2 was transplanted into syngeneic RAG2/ mice (injected with isotype control, anti-NK1.1, or anti–IFN-G monoclonal antibodies) or RAG2/x Gc/ mice. Tumor masses were harvested 15 d after transplantation, disaggregated into single-cell suspensions, and analyzed by IHC (A) or FACS (B) to measure the percentage of M1 and
M2 macrophages as defined by MHC class II and CD206 expression of CD68+ events (for IHC) or MHC class II and Ly6C expression of CD11b+ populations
(for FACS), respectively. (C and D) An example of the flow cytometry gating to quantitate M1 and M2 macrophages. M1 macrophages are 7AAD, CD45+,
Ly 6Clo, MHC class IIhi, F4/80+, CD206lo cells. M2 macrophages are 7AAD, CD45+, Ly6Clo, MHC classIIlo, F4/80+, CD206hi cells. (E) Cultured supernatant from
single-cell suspensions were assessed for production of the indicated cytokines after 24 h of culture. (F) TAMs were sorted from harvested tumors at day
15, and genes associated with classically activated M1 type genes, such as iNOS and TNF, or alternatively activated M2 type genes, such as Arginase,
eCAD, and Gas3, were measured by quantitative PCR. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Error bars are represented by ± SEM. Each symbol represents
a different mouse. Results were reproduced at least once.
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sarcoma cell lines derived from RAG-deficient mice reproducibly approximates 40%. Moreover, the regressor frequency
of MCA-induced sarcomas generated in mice lacking RAG
and Gc is 60–70% in two independent experiments. These
results suggest a quantitative nature to the immunoediting
process, whereby a certain degree of basal immune function
is associated with quantifiable levels of tumor sculpting, which
can be measured by the regressor frequency. Because a majority of MCA cell lines generated from RAG2/x Gc/
mice are regressors, we speculate that the primary tumor cell
repertoire consists of mostly immunogenic tumor cells that
are immunologically heterogeneous (O’Sullivan et al., 2011).
This heterogeneity can be partially sculpted by innate immunity in RAG2/ mice or fully sculpted by the complete immune system in WT mice. It should be noted that we have
never been able to isolate regressors from MCA-induced sarcomas that develop in WT mice (regressor frequency of 0%
of 50 cell lines). These results confirm that cancer immunoediting of MCA-induced sarcomas is quite robust in WT mice
and further validate that immune escape is an essential hallmark of cancer cells (Hanahan and Weinberg, 2011).
We have provided evidence that the innate immune system
can edit tumors and point to M1 macrophages as participants
1878

in this process. M1 macrophages are activated classically via IFN-G and function in the removal of intracellular pathogens (Gordon and Taylor, 2005). In the
context of cancer, M1 macrophages can promote tumor
elimination via activation of Th1 pathways and secretion
of tumoricidal levels of nitric oxide (Sica et al., 2008).
In our studies, we have defined CD45+CD11b+MHC
class IIhiCD206loLy6Clo cells as M1 macrophages based
not only on their phenotype but also on their classical
requirement for IFN-G for their generation. Using
this definition, we found a striking correlation between
the presence of M1 macrophages and productive immune responses to regressor tumors. The administration of reagents that increased M1 percentages, such
as CD40 agonist, enhanced editing, whereas treatments
that decreased M1 percentages, such as NK cell depletion and
anti–IFN-G mAb blocked editing.
Our findings support an anti-tumor function for macrophages that is consistent with studies performed almost 40 yr
ago, when it was shown that activated macrophages from
infected mice (Hibbs et al., 1971) could kill syngeneic transformed murine embryonic fibroblasts, but not primary nontransformed murine embryonic fibroblasts (Hibbs et al., 1972)
in vitro. This tumoricidal activity of macrophages required
cell-cell contact and was induced largely by the cytokine IFN-G
(Pace et al., 1983; Schreiber et al., 1983) in combination with
additional signals such as LPS (Weinberg et al., 1978) or muramyl dipeptide (Kleinerman et al., 1983). Although we have
not shown that regressor tumor cells are killed by TAMs, we
have observed that regressor tumor cells can be killed effectively
by IFN-G–stimulated bone marrow macrophages in vitro (unpublished data). Our attempts to demonstrate the tumoricidal
activity of regressor-associated macrophages was limited by
the poor viability of sorted TAMs. Furthermore, the requirement of macrophages in immunoediting could not be tested,
as treatment with clodronate-encapsulated liposomes failed to
deplete macrophages in tumors, even though depletion of
CD11b+ macrophages was achieved in the spleens of tumor
Tumor editing by macrophages and NK cells | O’Sullivan et al.
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Figure 9. In vivo administration of CD40 agonist in
RAG2/x Gc/ mice induces effective immunoediting
and intratumoral M1 macrophages. Regressor cell line 2 was
transplanted into RAG2/x Gc/ mice receiving a single dose
of either control rat IgG or anti-CD40 agonistic monoclonal
antibodies on day 5. Tumor growth was measured over time.
(A) Tumor masses were converted into passaged daughter cell
lines which were transplanted into syngeneic WT mice and
assessed for tumor formation (number of cell lines and mice
are indicated in the figure). Tumor-free mice were defined to
have a nonenlarging mass <9 mm in average diameter by
day 40. (B) At day 15 after transplantation, tumor masses
were disaggregated into single-cell suspensions, and the percentage of M1 (top) and M2 (bottom) macrophages of CD11b+
events for each condition were quantified. *, P < 0.05;
***, P < 0.001. Error bars are represented by ± SEM. Each symbol
represents a different mouse. Results were reproduced at
least once.
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polarization and subsequent editing in RAG2/ mice. Although we cannot rule out the contribution of myeloid populations in IFN-G production, sorted M1 and M2 TAMs do
not show any IFN-G transcript (unpublished data), suggesting
that NK cells are the predominant producers of IFN-G in the
RAG2/ host. It is not known what induces IFN-G production by NK cells in our system, but our preliminary studies indicate that MCA-induced sarcoma cells are incapable of
directly eliciting IFN-G production from NK cells in vitro.
Interestingly, IL-12p40 was shown to be required for MCA
sarcoma surveillance (Smyth et al., 2000), so it is possible that
local IL-12 production could stimulate NK cells to produce
IFN-G to mediate editing in the absence of adaptive immunity. It should be noted that in RAG2/x Gc/ mice lacking NK cells, editing could be restored with CD40 agonist
treatment, suggesting that direct interaction between NK cells
and tumor cells is not needed for tumor editing as long as M1
macrophages are present.
Our model is based on the postulate that immunogenic
regressors, in the presence of M1 macrophages, are converted
into nonimmunogenic progressors, but we have not identified
the molecular basis of this phenotypic conversion. Recent
studies have also found that certain tumor cells can evade macrophage killing/phagocytosis by expressing high levels of CD47
(Jaiswal et al., 2009; Majeti et al., 2009) and/or low levels of
calreticulin (Chao et al., 2010). Other studies have implicated
calreticulin exposure as a key initiator of innate immune responses to tumor cells, leading to antigen presentation and productive adaptive antitumor responses, and the blockade of these
pathways could be a mechanism of tumor escape (Zitvogel et al.,
2010). We did not find differences in the interaction between
bone marrow–derived macrophages and regressor versus
progressor tumor cells in vitro (unpublished data). Furthermore, our preliminary studies indicate that CD47 and calreticulin are not different between regressor and progressor cells
in vitro. Future studies will compare the gene expression
profiles of regressor and progressor cells to identify pathways that may mediate innate cell recognition/editing. Our
matched regressor/passaged regressor cells will be critical for
these experiments.
In summary, we document the generation and initial
characterization of a novel set of unedited MCA-induced sarcoma cell lines that may be highly stimulatory for the innate
immune system. The enhanced accumulation of M1 macrophages in these highly immunogenic tumors suggests that
they can serve as models to study the early events that lead to
the generation of M1 macrophages in regressing tumors. We
also show that the innate immune system in RAG/ mice
contains sufficient cellular machinery to perform sculpting
of MCA-induced sarcomas. This cellular machinery includes
NK cells that produce IFN-G to activate macrophages to function as innate editors. This cascade can lead to tumor elimination in the presence of adaptive immunity and/or editing in
the absence of adaptive immunity. Finally, we introduce a
quantitative dimension to the sculpting phase of cancer immunoediting by showing that the percentage of regressor cell
1879
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bearing mice (unpublished data). Nevertheless, we favor the
interpretation that M1 macrophages are the most likely editor
in mice that lack adaptive cells, given their abundance in the
tumor, their enhanced presence in response to IFN-G and
NK cell activity, and their known tumoricidal activity.
Recent studies indicate that macrophage tumoricidal activity could be enhanced in vitro and in vivo upon administration of CD40 agonistic antibodies (Buhtoiarov et al., 2005;
Rakhmilevich et al., 2008; Beatty et al., 2011). Notably, Beatty
et al. (2011) investigated the role of tumoricidal macrophages
activated in vivo with CD40 agonist treatments in the rejection
of pancreatic ductal adenocarcinoma (PDA). After demonstrating the efficacy of the anti-CD40 agonist mAb CP-870,893
in human patients, the authors used a mouse model of PDA
to investigate the mechanism of tumor rejection with CD40
agonist treatment. To their surprise, the results indicated that
CD40-stimulated macrophages, independent of T cell activity,
are sufficient to mediate PDA rejection in vivo. Similarly, we
have found that CD40 agonist treatment of RAG2/x Gc/
mice can induce tumor editing in the absence of adaptive
immunity and NK cells, thereby suggesting that macrophages
are sufficient for tumor editing. In contrast to the Beatty study,
we did not see tumor rejection, suggesting that MCA sarcomas
require adaptive cells for their regression. Our studies also show
that unmanipulated macrophages are capable of editing through
IFN-G and NK cells without the use of CD40 agonists.
We found that the accumulation of M1 macrophages in
regressor tumors required IFN-G and NK cells. The participation of NK cells in immunosurveillance against certain types
of tumors has been clearly documented in studies showing
increased tumor incidences in mice lacking NK cells or molecules associated with NK cell recognition or effector function
(Smyth et al., 2002, 2006; Raulet and Guerra, 2009), such as
NKp46 (Gazit et al., 2006), natural killer group 2D (NKG2D;
Guerra et al., 2008), DNAX accessory molecule-1 (Gilfillan
et al., 2008; Iguchi-Manaka et al., 2008), perforin (van den
Broek et al., 1996; Street et al., 2001), IFN-G (Street et al.,
2001), or TNF-related apoptosis-inducing ligand (Cretney
et al., 2002). Therefore, we considered the possibility that
there might be increased NK cell killing of MCA-induced
sarcoma cells from RAG2/x Gc/ versus RAG2/ or
WT mice. However, we did not find major differences in the
susceptibility of unedited versus edited tumors to NK cell killing. These results are consistent with recent studies showing
that NKG2D, an activating receptor on NK cells that mediates
tumor recognition and killing, did not play a role in the surveillance of MCA-induced sarcomas (Guerra et al., 2008). In
this study, NKG2D-deficient mice had similar incidences of
MCA-induced sarcomas but were more susceptible to tumor
formation in prostate cancer and B lymphoma model systems,
suggesting that the role of NK cells in destroying tumor cells
could be dependent on the site of tumor formation. For MCAinduced sarcomas, we advocate that one role of NK cells in
eliminating and/or sculpting tumors in the absence of adaptive
immunity may be as a source of IFN-G. This is based on findings that NK cells and IFN-G are necessary for M1 macrophage
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lines generated from MCA-induced sarcomas is reproducible
and correlates with the level of immune pressure in the tumorbearing host.
MATERIALS AND METHODS
Experimental procedures. All experiments involving mice were conducted under animal protocols approved by the Washington University
Animal Studies Committee and the University of California, San Diego
Institutional Animal Care and Use Committee (IACUC protocol #S06201)
and were in accordance with ethical guidelines determined by the Peter Mac
Animal Experimental Ethics Committee.

Cell lines. MCA-induced and passaged daughter sarcomas were isolated and
passaged in vitro as previously described (Shankaran et al., 2001; Smyth et al.,
2005). In brief, tumor chunks were made into single-cell suspensions by mincing
and collagenase treatment in HBSS (1 mg/ml type IA; Sigma-Aldrich), and
multiple vials were frozen at passage 2. For transplantation and cytotoxicity assays,
passage 2 cell lines were thawed, expanded, and studied at passage 4–8. Cell lines
were maintained in RPMI 1640 (Cambrex) supplemented with 10% FCS
(HyClone) as previously described (Shankaran et al., 2001; Bui et al., 2006).
1880

Antibodies and FACS analysis. On various days after transplantation,
tumors were excised from mice, minced, and treated with 1 mg/ml type IA
collagenase (Sigma-Aldrich) as previously described (Weinberg et al., 1978).
Cells were vigorously resuspended, washed in FACS buffer (PBS + 1%
FCS+0.05%NaN3; Sigma-Aldrich) and filtered before staining. Antibodies
to CD45, F4/80, NK1.1, CD69, CD80, CD206, Ly6C, CD11b, I-A/I-E, 1A8,
and streptavidin PE were obtained from BD. Staining was conducted for
15–20 min at 4° in FACS tubes containing 1–2 million total cells, 0.5–1 μl
of antibody, 1 μl of anti-CD16/32, and 100 μl of FACS buffer. 7AAD (EMD
Millipore) or propidium iodide (Sigma-Aldrich) was added at 1 μg/ml immediately before FACS analysis. M1-type and M2-type macrophages were
gated as previously described (Movahedi et al., 2010; see Fig. 8). F4/80
and CD68 were used to detect macrophages in FACS assays or in IHC
assays. F4/80 marks all monocyte lineage cells, and CD68 marks mature
tissue macrophages that are in tumors (Van Ginderachter et al., 2006; Wang
et al., 2012).
Immunohistochemistry. Fresh tumor nodules were harvested, OCTembedded, and snap frozen in cooled isopentane. Tissue blocks were cut on
a cryostat into 6-μm-thick sections, mounted onto poly-l-lysine slides, airdried overnight, and post-fixed for 10 min in acetone before staining. Purified rat anti–mouse CD16/CD32 was used to block for 20 min (BD; dilution
1:50) when appropriate. Biotin-conjugated rat anti–mouse I-A/I-E (eBioscience; dilution 1:100; 1 h at room temperature) and biotin-conjugated rat
anti–mouse CD206 (BioLegend; dilution 1:100, 1 h at room temperature)
staining was revealed using streptavidin-horseradish peroxidase (Vector Laboratories; 30 min at room temperature) followed by amino-ethyl-carbazole
as chromogen (BD; 10-15 min at room temperature). Purified rat anti–mouse
CD68 (BioLegend; dilution 1:100) staining was detected using a biotinconjugated rabbit polyclonal anti–rat IgG, mouse adsorbed (Vector; dilution
1:200). Immunostained tissue sections were examined with a Leica DM
2500 or Nikon Eclipse E800 microscope; images were captured with a Leica
DFC 420 or Nikon DXM 1200 digital camera, respectively. Quantitative
analysis of MHC-II+, CD68+, CD206+ cells was obtained by counting at
least 10 high power fields of tissue sections at 200× magnification.
Cell sorting. TAMs were sorted from tumor cell suspensions on a BD
FACSAria. We defined M1 macrophages as 7AAD, CD45+, Ly 6Clo, MHC
class IIhi, F4/80+, CD206lo cells, and M2 macrophages as 7AAD, CD45+,
Ly6Clo, MHC classIIlo, F4/80+, CD206hi cells.
Quantitative PCR (qPCR). TAM RNA was isolated with a QIAGEN
RNeasy Mini kit before reverse transcription with Applied Biosystems
High-Capacity cDNA Reverse Transcription kit. qPCR reactions were
performed on the CFX96 Touch Real-Time PCR Detection System (Bio-Rad
Laboratories). Primers for the detection of other transcripts used are as
follows: m18s forward, 5-CGCGGTTCTATTTTGTTGGT-3, m18s reverse,
5-AACCTCCGACTTTCGTTCTTG-3; mTNFA forward, 5-CATCTTCTCAAAATTCGAGTGACAA-3, TNF reverse, 5-TGGGAGTAGACAAGGTACAACCC-3; miNOS forward, 5-CCCTTCAATGGTTGGTACATGG-3, miNOS reverse, 5-ACATTGATCTCCGTGACAGCC-3;
mArginase forward, 5-GAACACGGCAGTGGCTTTAAC-3, mArginase
reverse, 5-TGCTTAGCTCTGTCTGCTTTGC-3; mE-cadherin forward,
Tumor editing by macrophages and NK cells | O’Sullivan et al.
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Mice and MCA induction. Tumor induction by MCA was performed as
previously described (Smyth et al., 2000; Shankaran et al., 2001). In brief, cohorts
of C57BL/6-strain WT (Taconic), RAG2/, RAG1/, and RAG2/x
Gc/ mice were injected with MCA dissolved in peanut oil at various doses.
Experiment 1 was performed in St. Louis and used RAG2/x Gc/ mice
generated by breeding IL-2RGc/ mice (C57/BL6 N10+1F7-strain; The
Jackson Laboratory) to C57BL/6 RAG2/ mice (Taconic). Genotyping
was performed using PCR (for IL-2RGc, following The Jackson Laboratories protocol [http://jaxmice.jax.org/strain/003174.html]) or by Southern
blot for RAG2 (Shinkai et al., 1992). Genomic microsatellite analysis showed
that the RAG2/x Gc/ mice contained C57BL/6 markers at 97% of the
loci tested (3% 129/Sv markers). To control for interinstitutional breeding,
minor strain differences, and housing variability, the RAG2/ mice used in
MCA experiment 1 were outcrossed from (RAG2/x Gc/) x RAG2/
breeding performed in-house. Tumors in mice were measured as previously
described (Shankaran et al., 2001; Koebel et al., 2007). In experiment 1, a
dose of MCA was used such that all MCA-treated mice developed tumors.
Experiment 2 was performed at the Peter Mac facility in Australia and used
RAG2/x Gc/ mice, which were provided by the Walter and Eliza Hall
Institute (Bundoora), and C57BL/6 and RAG1/ mice as previously described
(Smyth et al., 2000). To rule out that RAG2/x Gc/ tumor cell lines were
rejected based on minor strain differences, we also transplanted RAG2/x
Gc/ regressor cell lines into F1 (C57BL/6 × 129) mice (n = 30; Taconic)
and obtained identical growth patterns as in C57BL/6 mice (National Cancer
Institute, Frederick Rockville, MD). For some tumor transplantation experiments, RAG2/x Gc/ recipient mice were purchased from Taconic. No
differences in tumor growth were observed in RAG2/x Gc/ recipient
mice purchased from Taconic Farms or bred in-house.
We discovered in the process of routine genotyping of our mice for
the current study that the RAG2/ 129/Sv mice previously obtained
from Taconic Farms (RAGN12 model) and used in our 2001 publication
(Shankaran et al., 2001) contained the C57BL/6 NK-C locus. Microsatellite
analysis confirmed that these mice were virtually congenic at the NK-C locus
and contained Y22 cM of C57BL/6 sequence encompassing the following
genes/markers: D6MIT261, D6MIT105, D6MIT018, D6MIT111, Nkrp1a,
Nkrp1c, CD69, Nkg2d, Nkg2a, and Ly49a (Yokoyama and Plougastel, 2003).
These mice were therefore designated 129/SvEv.cNK-C.B6 RAG2/ mice.
Because the NK-C gene locus displays allelic polymorphism and can contribute to part of the difference in NK cell activity between the C57BL/6 and
129/Sv strain (Yokoyama and Plougastel, 2003), new sets of MCA-induced
sarcomas were generated using RAG2/ mice that had been bred by Taconic
Farms to be on a pure 129/SvEv background (129S6/SvEvTac-Rag2tm1Fwa).
This new set of MCA-induced sarcomas was published in Koebel et al., 2007
and further studied in Fig. 3.

Tumor transplantation. Subconfluent tumor cell lines were harvested
by trypsinization, washed 3 times with PBS, and injected at 106 cells subcutaneously into recipient C57BL/6, (129/Sv x C57BL/6) F1, RAG2/, or
RAG2/x Gc/ strain mice as previously described (Shankaran et al.,
2001; Smyth et al., 2005; Bui et al., 2006). RAG2/ mice were injected i.p.
with 200 μg of either control hamster IgG (PIP), anti-NK1.1 (PK136), or
anti–IFN-G (H22) on days 2 and 0 and every 4 d after until tumor harvest.
RAG2/x Gc/ mice were injected i.p. with 200 μg either control rat IgG
or anti-CD40 agonist (FGK 45.5) on day 5. Mice were monitored for tumor
growth by measurement of mean tumor diameter, defined as the mean of the
two maximum dimensions of the tumor mass.
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5-ACTTGGGGACAGCAACATCA-3, mE-cadherin reverse, 5-GGGTTTAAATCGGCCAGCAT-3; Gas3 forward, 5-GTAATGGACACACGACTGATC-3, Gas3 reverse, 5-GGAGTAGTCAGTGTTGACATG-3.
Cytokine secretion assay. On day 15 after transplantation, tumors were
excised from mice, minced, and treated with 1 mg/ml type IA collagenase
(Sigma-Aldrich) as previously described (Weinberg et al., 1978). Filtered
tumor/immune cell suspensions were plated in triplicate wells at 40,000 cells/
well in 100 μl for 24 h at 37°C. Supernatant was analyzed for cytokines using
the mouse inflammation cytometric bead array kit from BD.
Statistical Analysis. Statistical significance between two groups was determined by the Welch’s t test using two-tailed analysis to obtain p-values. The
Log-Rank test was used to compare the survival of mice across tumor transplantation or induction conditions. Error bars are depicted using the SEM.
All experiments were done at least twice.

Submitted: 6 July 2011
Accepted: 1 September 2012

REFERENCES
Balkwill, F., and L.M. Coussens. 2004. Cancer: an inflammatory link.
Nature. 431:405–406. http://dx.doi.org/10.1038/431405a
Beatty, G.L., E.G. Chiorean, M.P. Fishman, B. Saboury, U.R. Teitelbaum,
W. Sun, R.D. Huhn, W. Song, D. Li, L.L. Sharp, et al. 2011. CD40
agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 331:1612–1616. http://dx.doi.org/
10.1126/science.1198443
Ben-Neriah, Y., and M. Karin. 2011. Inflammation meets cancer, with NF-KB
as the matchmaker. Nat. Immunol. 12:715–723. http://dx.doi.org/10
.1038/ni.2060
Boon, T., and O. Kellermann. 1977. Rejection by syngeneic mice of cell
variants obtained by mutagenesis of a malignant teratocarcinoma cell line.
Proc. Natl. Acad. Sci. USA. 74:272–275. http://dx.doi.org/10.1073/pnas.74
.1.272
Buhtoiarov, I.N., H. Lum, G. Berke, D.M. Paulnock, P.M. Sondel, and
A.L. Rakhmilevich. 2005. CD40 ligation activates murine macrophages
via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J. Immunol. 174:6013–6022.
Bui, J.D., L.N. Carayannopoulos, L.L. Lanier, W.M. Yokoyama, and R.D.
Schreiber. 2006. IFN-dependent down-regulation of the NKG2D
ligand H60 on tumors. J. Immunol. 176:905–913.
Cao, X., E.W. Shores, J. Hu-Li, M.R. Anver, B.L. Kelsall, S.M. Russell, J.
Drago, M. Noguchi, A. Grinberg, E.T. Bloom, et al. 1995. Defective
lymphoid development in mice lacking expression of the common cytokine receptor G chain. Immunity. 2:223–238. http://dx.doi.org/10.1016/
1074-7613(95)90047-0
Chao, M.P., S. Jaiswal, R. Weissman-Tsukamoto, A.A. Alizadeh, A.J.
Gentles, J. Volkmer, K. Weiskopf, S.B. Willingham, T. Raveh,
JEM Vol. 209, No. 10

1881

Downloaded from jem.rupress.org on December 11, 2012

We thank all members of the Schreiber, Smyth, and Bui Laboratories. We would like
to thank Janelle Sharkey for excellent technical assistance and Jessica Archambault,
Tiffany Irwin, and Michelle Stirling for animal maintenance.
J.D. Bui is supported by grants from the Cancer Research Institute, National
Institutes of Health (NIH; CA128893, CA157885), the American Cancer Society
(ACS-IRG #70-002), the Cancer Research Coordinating Committee (6-444951-34384),
the Concern Foundation, and The Hartwell Foundation. R.D. Schreiber is supported by
NIH grants CA43059 and CA107527, a grant from the Ludwig Institute for Cancer
Research, and the Rhea Rosemary Finnell Clinical Investigation Grant from the Cancer
Research Institute. R. Uppaluri is supported by K08 CA090403. M.J. Smyth is
supported by an Australia Fellowship and a Program Grant from the National Health
and Medical Research Council of Australia and a project grant from the Association of
International Cancer Research. M.W.L. Teng is supported by a Cancer Council of
Victoria project grant and a National Health and Medical Research Council Peter
Doherty Postdoctoral Fellowship. S.F. Ngiow is supported by a Cancer Research
Institute Pre-doctoral scholarship. The work cited in this publication was performed in
a facility supported by National Center for Research Resources grant C06 RR012466.
The authors do not report any competing financial interests.

C.Y. Park, R. Majeti, and I.L. Weissman. 2010. Calreticulin Is the
Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is
Counterbalanced by CD47. Science Translational Medicine. 2:63ra94.
Cretney, E., K. Takeda, H. Yagita, M. Glaccum, J.J. Peschon, and M.J.
Smyth. 2002. Increased susceptibility to tumor initiation and metastasis
in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol.
168:1356–1361.
Crowe, N.Y., M.J. Smyth, and D.I. Godfrey. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced
sarcomas. J. Exp. Med. 196:119–127. http://dx.doi.org/10.1084/jem
.20020092
Dunn, G.P., L.J. Old, and R.D. Schreiber. 2004a. The immunobiology of
cancer immunosurveillance and immunoediting. Immunity. 21:137–148.
http://dx.doi.org/10.1016/j.immuni.2004.07.017
Dunn, G.P., L.J. Old, and R.D. Schreiber. 2004b. The three Es of cancer
immunoediting. Annu. Rev. Immunol. 22:329–360. http://dx.doi.org/10
.1146/annurev.immunol.22.012703.104803
Dunn, G.P., A.T. Bruce, K.C.F. Sheehan, V. Shankaran, R. Uppaluri, J.D.
Bui, M.S. Diamond, C.M. Koebel, C. Arthur, J.M. White, and R.D.
Schreiber. 2005. A critical function for type I interferons in cancer
immunoediting. Nat. Immunol. 6:722–729. http://dx.doi.org/10.1038/
ni1213
Flood, P.M., H. Schreiber, and Y. Ron. 1987. Protective immunity to progressive tumors can be induced by antigen presented on regressor tumors.
J. Immunol. 138:3573–3579.
Gazit, R., R. Gruda, M. Elboim, T.I. Arnon, G. Katz, H. Achdout, J.
Hanna, U. Qimron, G. Landau, E. Greenbaum, et al. 2006. Lethal influenza infection in the absence of the natural killer cell receptor gene
Ncr1. Nat. Immunol. 7:517–523. http://dx.doi.org/10.1038/ni1322
Ghassabeh, G.H., P. De Baetselier, L. Brys, W. Noël, J.A. Van Ginderachter,
S. Meerschaut, A. Beschin, F. Brombacher, and G. Raes. 2006.
Identification of a common gene signature for type II cytokine-associated
myeloid cells elicited in vivo in different pathologic conditions. Blood.
108:575–583. http://dx.doi.org/10.1182/blood-2005-04-1485
Gilfillan, S., C.J. Chan, M. Cella, N.M. Haynes, A.S. Rapaport, K.S. Boles, D.M.
Andrews, M.J. Smyth, and M. Colonna. 2008. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting
cells and tumors. J. Exp. Med. 205:2965–2973. http://dx.doi.org/10
.1084/jem.20081752
Gordon, S., and P.R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5:953–964. http://dx.doi.org/10.1038/nri1733
Guerra, N., Y.X. Tan, N.T. Joncker, A. Choy, F. Gallardo, N. Xiong,
S. Knoblaugh, D. Cado, N.M. Greenberg, and D.H. Raulet. 2008.
NKG2D-deficient mice are defective in tumor surveillance in models of
spontaneous malignancy. Immunity. 28:571–580. http://dx.doi.org/10
.1016/j.immuni.2008.02.016
Hanahan, D., and R.A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell. 144:646–674. http://dx.doi.org/10.1016/j.cell.2011.02.013
Hibbs, J.B. Jr., L.H. Lambert Jr., and J.S. Remington. 1971. Resistance to
murine tumors conferred by chronic infection with intracellular protozoa,
Toxoplasma gondii and Besnoitia jellisoni. J. Infect. Dis. 124:587–592.
http://dx.doi.org/10.1093/infdis/124.6.587
Hibbs, J.B. Jr., L.H. Lambert Jr., and J.S. Remington. 1972. Control of carcinogenesis: a possible role for the activated macrophage. Science. 177:998–
1000. http://dx.doi.org/10.1126/science.177.4053.998
Iguchi-Manaka, A., H. Kai, Y. Yamashita, K. Shibata, S. Tahara-Hanaoka,
S.I. Honda, T. Yasui, H. Kikutani, K. Shibuya, and A. Shibuya. 2008.
Accelerated tumor growth in mice deficient in DNAM-1 receptor.
J. Exp. Med. 205:2959–2964. http://dx.doi.org/10.1084/jem.20081611
Jaiswal, S., C.H.M. Jamieson, W.W. Pang, C.Y. Park, M.P. Chao, R. Majeti,
D. Traver, N. van Rooijen, and I.L. Weissman. 2009. CD47 is upregulated
on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 138:271–285. http://dx.doi.org/10.1016/j.cell.2009.05.046
Kleinerman, E.S., K.L. Erickson, A.J. Schroit, W.E. Fogler, and I.J. Fidler.
1983. Activation of tumoricidal properties in human blood monocytes
by liposomes containing lipophilic muramyl tripeptide. Cancer Res.
43:2010–2014.
Koebel, C.M., W. Vermi, J.B. Swann, N. Zerafa, S.J. Rodig, L.J. Old,
M.J. Smyth, and R.D. Schreiber. 2007. Adaptive immunity maintains

Published August 27, 2012

1882

Smyth, M.J., K.Y. Thia, S.E. Street, E. Cretney, J.A. Trapani, M. Taniguchi,
T. Kawano, S.B. Pelikan, N.Y. Crowe, and D.I. Godfrey. 2000.
Differential tumor surveillance by natural killer (NK) and NKT cells.
J. Exp. Med. 191:661–668. http://dx.doi.org/10.1084/jem.191.4.661
Smyth, M.J., N.Y. Crowe, and D.I. Godfrey. 2001. NK cells and NKT
cells collaborate in host protection from methylcholanthrene-induced
fibrosarcoma. Int. Immunol. 13:459–463. http://dx.doi.org/10.1093/
intimm/13.4.459
Smyth, M.J., Y. Hayakawa, K. Takeda, and H. Yagita. 2002. New aspects of
natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer.
2:850–861. http://dx.doi.org/10.1038/nrc928
Smyth, M.J., J. Swann, E. Cretney, N. Zerafa, W.M. Yokoyama, and Y.
Hayakawa. 2005. NKG2D function protects the host from tumor initiation.
J. Exp. Med. 202:583–588. http://dx.doi.org/10.1084/jem.20050994
Smyth, M.J., G.P. Dunn, and R.D. Schreiber. 2006. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing
tumor development and shaping tumor immunogenicity. Adv. Immunol.
90:1–50. http://dx.doi.org/10.1016/S0065-2776(06)90001-7
Street, S.E.A., E. Cretney, and M.J. Smyth. 2001. Perforin and interferongamma activities independently control tumor initiation, growth, and metastasis. Blood. 97:192–197. http://dx.doi.org/10.1182/blood.V97.1.192
Street, S.E.A., Y. Hayakawa, Y. Zhan, A.M. Lew, D. MacGregor, A.M.
Jamieson, A. Diefenbach, H. Yagita, D.I. Godfrey, and M.J. Smyth.
2004. Innate immune surveillance of spontaneous B cell lymphomas by
natural killer cells and gammadelta T cells. J. Exp. Med. 199:879–884.
http://dx.doi.org/10.1084/jem.20031981
Takahashi, K., and S. Yamanaka. 2006. Induction of pluripotent stem cells
from mouse embryonic and adult fibroblast cultures by defined factors.
Cell. 126:663–676. http://dx.doi.org/10.1016/j.cell.2006.07.024
Takeda, K., M.J. Smyth, E. Cretney, Y. Hayakawa, N. Kayagaki, H. Yagita,
and K. Okumura. 2002. Critical role for tumor necrosis factor-related
apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195:161–169. http://dx.doi.org/10.1084/
jem.20011171
van den Broek, M.E., D. Kägi, F. Ossendorp, R. Toes, S. Vamvakas,
W.K. Lutz, C.J. Melief, R.M. Zinkernagel, and H. Hengartner. 1996.
Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med.
184:1781–1790. http://dx.doi.org/10.1084/jem.184.5.1781
Van Ginderachter, J.A., S. Meerschaut, Y. Liu, L. Brys, K. De Groeve, G.
Hassanzadeh Ghassabeh, G. Raes, and P. De Baetselier. 2006. Peroxisome
proliferator-activated receptor gamma (PPARgamma) ligands reverse
CTL suppression by alternatively activated (M2) macrophages in cancer.
Blood. 108:525–535. http://dx.doi.org/10.1182/blood-2005-09-3777
Vesely, M.D., M.H. Kershaw, R.D. Schreiber, and M.J. Smyth. 2011. Natural
innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29:235–
271. http://dx.doi.org/10.1146/annurev-immunol-031210-101324
Wang, S.-C., J.-H. Hong, C. Hsueh, and C.-S. Chiang. 2012. Tumorsecreted SDF-1 promotes glioma invasiveness and TAM tropism toward
hypoxia in a murine astrocytoma model. Lab. Invest. 92:151–162. http://
dx.doi.org/10.1038/labinvest.2011.128
Weinberg, J.B., H.A. Chapman Jr., and J.B. Hibbs Jr. 1978. Characterization
of the effects of endotoxin on macrophage tumor cell killing. J. Immunol.
121:72–80.
Yokoyama, W.M., and B.F.M. Plougastel. 2003. Immune functions encoded by the natural killer gene complex. Nat. Rev. Immunol. 3:304–
316. http://dx.doi.org/10.1038/nri1055
Zitvogel, L., O. Kepp, L. Senovilla, L. Menger, N. Chaput, and G. Kroemer.
2010. Immunogenic tumor cell death for optimal anticancer therapy:
the calreticulin exposure pathway. Clin. Cancer Res. 16:3100–3104.
http://dx.doi.org/10.1158/1078-0432.CCR-09-2891

Tumor editing by macrophages and NK cells | O’Sullivan et al.

Downloaded from jem.rupress.org on December 11, 2012

occult cancer in an equilibrium state. Nature. 450:903–907. http://dx.doi
.org/10.1038/nature06309
Kripke, M.L. 1974. Antigenicity of murine skin tumors induced by ultraviolet
light. J. Natl. Cancer Inst. 53:1333–1336.
Lewis, C.E., and J.W. Pollard. 2006. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66:605–612. http://dx.doi
.org/10.1158/0008-5472.CAN-05-4005
Lum, H.D., I.N. Buhtoiarov, B.E. Schmidt, G. Berke, D.M. Paulnock, P.M.
Sondel, and A.L. Rakhmilevich. 2006. Tumoristatic effects of anti-CD40
mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha. Immunology. 118:261–270. http://dx.doi.org/10.1111/
j.1365-2567.2006.02366.x
Majeti, R., M.P. Chao, A.A. Alizadeh, W.W. Pang, S. Jaiswal, K.D. Gibbs
Jr., N. van Rooijen, and I.L. Weissman. 2009. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid
leukemia stem cells. Cell. 138:286–299. http://dx.doi.org/10.1016/j.cell
.2009.05.045
Martinez, F.O., L. Helming, and S. Gordon. 2009. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol.
27:451–483. http://dx.doi.org/10.1146/annurev.immunol.021908.132532
Movahedi, K., D. Laoui, C. Gysemans, M. Baeten, G. Stangé, J. Van den
Bossche, M. Mack, D. Pipeleers, P. In’t Veld, P. De Baetselier, and J.A.
Van Ginderachter. 2010. Different tumor microenvironments contain
functionally distinct subsets of macrophages derived from Ly6C(high)
monocytes. Cancer Res. 70:5728–5739. http://dx.doi.org/10.1158/00085472.CAN-09-4672
O’Sullivan, T., G.P. Dunn, D.Y. Lacoursiere, R.D. Schreiber, and J.D. Bui.
2011. Cancer immunoediting of the NK group 2D ligand H60a. J. Immunol.
187:3538–3545. http://dx.doi.org/10.4049/jimmunol.1100413
Pace, J.L., S.W. Russell, R.D. Schreiber, A. Altman, and D.H. Katz. 1983.
Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma. Proc. Natl. Acad. Sci. USA. 80:3782–
3786. http://dx.doi.org/10.1073/pnas.80.12.3782
Rakhmilevich, A.L., I.N. Buhtoiarov, M. Malkovsky, and P.M. Sondel. 2008.
CD40 ligation in vivo can induce T cell independent antitumor effects
even against immunogenic tumors. Cancer Immunology. Immunotherapeutics.
57:1151–1160. http://dx.doi.org/10.1007/s00262-007-0447-4
Raulet, D.H., and N. Guerra. 2009. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol.
9:568–580. http://dx.doi.org/10.1038/nri2604
Schreiber, R.D., J.L. Pace, S.W. Russell, A. Altman, and D.H. Katz. 1983.
Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. J. Immunol.
131:826–832.
Schreiber, R.D., L.J. Old, and M.J. Smyth. 2011. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion.
Science. 331:1565–1570. http://dx.doi.org/10.1126/science.1203486
Shankaran, V., H. Ikeda, A.T. Bruce, J.M. White, P.E. Swanson, L.J. Old,
and R.D. Schreiber. 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature.
410:1107–1111. http://dx.doi.org/10.1038/35074122
Shinkai, Y., G. Rathbun, K.P. Lam, E.M. Oltz, V. Stewart, M.
Mendelsohn, J. Charron, M. Datta, F. Young, A.M. Stall, et al. 1992.
RAG-2-deficient mice lack mature lymphocytes owing to inability
to initiate V(D)J rearrangement. Cell. 68:855–867. http://dx.doi.org/
10.1016/0092-8674(92)90029-C
Sica, A., P. Larghi, A. Mancino, L. Rubino, C. Porta, M.G. Totaro, M.
Rimoldi, S.K. Biswas, P. Allavena, and A. Mantovani. 2008. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18:349–
355. http://dx.doi.org/10.1016/j.semcancer.2008.03.004

